SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) welcomed presentations from Pfizer and Sanofi at the WCBP conference, showcasing the transformative impact of MauriceFlex™ system on biotherapeutic development processes. MauriceFlex™ offers charge variant characterization and protein size analysis, addressing limitations in traditional methods. Presentations demonstrated its efficiency in AAV gene therapy development and collecting charge variants of complex proteins for downstream mass spectrometry characterization.

Positive

• MauriceFlex™ system addresses limitations in charge variant characterization and protein size analysis
• Efficiency demonstrated in AAV gene therapy development and collecting charge variants of complex proteins

Negative

• None.

MINNEAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in Washington D.C. The focus of these presentations was on the transformative impact of Bio-Techne's MauriceFlex™ system on their biotherapeutic development processes. MauriceFlex™, known for its automated capillary isoelectric focusing (icIEF), also enables protein charge fractionation, allowing charge variant characterization in downstream analytics like mass spectrometry. Like the Maurice™ system, the MauriceFlex™ also allows protein size analysis with capillary electrophoresis sodium dodecyl sulfate (CE-SDS).

Traditionally, the characterization of charge species in biotherapeutics has faced significant challenges owing to the limitations in analytical tools, resulting in the use of time-consuming and laborious methods for isolating individual variants. Consequently, charge variant characterization has been a pain point in biotherapeutic process development. Traditional methods like ion-exchange chromatography (IEX), often encounter bottlenecks in method optimization, particularly when dealing with complex molecules like enzymes, fusion proteins, and antibody-drug conjugates (ADCs).  MauriceFlex™, with the added capability of protein charge fractionation, offers a tool that reduces several pain points in charge species characterization, making it a routine assay that can be performed at multiple stages of process development.

During the WCBP conference, a presentation given by Xiaoping He and Sisi Huang from Pfizer, demonstrated how MauriceFlex™ enabled the characterization of charge species in AAV capsid proteins, helping the acceleration of AAV gene therapy development. The second presentation, by Qurrat (Anny) Ul-Ain and Zishuo (Toby) Cheng from Sanofi further showcased the MauriceFlex system's efficiency in collecting multiple charge variants of a complex protein with single-peak resolution for downstream mass spectrometry characterization.

"The discussions at the conference, particularly regarding the MauriceFlex™ system, reflect significant progress in the advancements of analytical techniques used in biotherapeutic development," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "These developments underscore the need for continuous innovation around analytical methods, empowering scientists to obtain critical information they need to produce the best-in-class therapeutics for patients worldwide".

About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scientists-at-the-wcbp-conference-highlight-advancements-in-protein-biotherapeutic-charge-heterogeneity-characterization-using-the-mauriceflex-system-302042854.html

SOURCE Bio-Techne Corporation

FAQ

What is the ticker symbol for Bio-Techne Corporation?

The ticker symbol for Bio-Techne Corporation is TECH.

What was the focus of the presentations at the WCBP conference?

The presentations focused on the transformative impact of MauriceFlex™ system on biotherapeutic development processes.

What are the capabilities of MauriceFlex™ system?

MauriceFlex™ offers charge variant characterization and protein size analysis, addressing limitations in traditional methods.

Who demonstrated the efficiency of MauriceFlex™ in AAV gene therapy development?

Xiaoping He and Sisi Huang from Pfizer demonstrated the efficiency of MauriceFlex™ in AAV gene therapy development.

What was the second presentation at the conference about?

The second presentation showcased the MauriceFlex system's efficiency in collecting multiple charge variants of a complex protein with single-peak resolution for downstream mass spectrometry characterization.